p120(ctn) acts as an inhibitory regulator of cadherin function in colon carcinoma cells. Aono S, Nakagawa S, Reynolds AB, Takeichi M (1999) J Cell Biol 145: 551-62 PTH induction of transcriptional activity of the cAMP response element-binding protein requires the serine 129 site and glycogen synthase kinase-3 activity, but not casein kinase II sites. Tyson DR, Swarthout JT, Jefcoat SC, Partridge NC (2002) Endocrinology 143: 674-82 The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LC (2001) J Biol Chem 276: 28570-7 Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. Corbett AH, Hong D, Osheroff N (1993) J Biol Chem 268: 14394-8 Urinary excretion of isoflavonoids and the risk of breast cancer. Zheng W, Dai Q, Custer LJ, Shu XO, Wen WQ, Jin F, Franke AA (1999) Cancer Epidemiol Biomarkers Prev 8: 35-40 Topoisomerase II and leukemia. Pendleton M, Lindsey RH, Felix CA, Grimwade D, Osheroff N (2014) Ann N Y Acad Sci 1310: 98-110 Assessment of dietary isoflavone intake among middle-aged Chinese men. Lee SA, Wen W, Xiang YB, Barnes S, Liu D, Cai Q, Zheng W, Shu XO (2007) J Nutr 137: 1011-6 Bioflavonoids as poisons of human topoisomerase II alpha and II beta. Bandele OJ, Osheroff N (2007) Biochemistry 46: 6097-108 Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Elsea SH, Westergaard M, Burden DA, Lomenick JP, Osheroff N (1997) Biochemistry 36: 2919-24 Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Robinson MJ, Corbett AH, Osheroff N (1993) Biochemistry 32: 3638-43 Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes. Osheroff N, Corbett AH, Elsea SH, Westergaard M (1994) Cancer Chemother Pharmacol 34 Suppl: S19-25 IL-6 production in human intestinal epithelial cells following stimulation with IL-1 beta is associated with activation of the transcription factor NF-kappa B. Parikh AA, Salzman AL, Kane CD, Fischer JE, Hasselgren PO (1997) J Surg Res 69: 139-44 Complement component C3 production in IL-1beta-stimulated human intestinal epithelial cells is blocked by NF-kappaB inhibitors and by transfection with ser 32/36 mutant IkappaBalpha. Moon MR, Parikh AA, Pritts TA, Fischer JE, Cottongim S, Szabo C, Salzman AL, Hasselgren PO (1999) J Surg Res 82: 48-55 Tyrosine kinase inhibition affects type 1 angiotensin II receptor internalization. Becker BN, Kondo S, Chen JK, Harris RC (1999) J Recept Signal Transduct Res 19: 975-93
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.